A pilot pragmatic randomized controlled trial of a nicotine metabolite ratio-guided smoking cessation intervention in a lung health and screening program
Authors:
Open Access
- 17 August 2024
- journal article
- research article
- Published by Elsevier in Drug and Alcohol Dependence Reports
- Vol. 12, 100275
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- National Institute of General Medical Sciences (U54-GM104941)
This publication has 15 references indexed in Scilit:
- Evaluating the Patient With a Pulmonary NoduleJAMA, 2022
- Screening for Lung CancerJAMA, 2021
- State Variation in Low-Dose Computed Tomography Scanning for Lung Cancer Screening in the United StatesJNCI: Journal of the National Cancer Institute, 2020
- Lung cancer screening: does pulmonary nodule detection affect a range of smoking behaviours?Journal of Public Health, 2018
- Smoking Cessation for Smokers Not Ready to Quit: Meta-analysis and Cost-effectiveness AnalysisAmerican Journal of Preventive Medicine, 2018
- Recent Trends in the Identification of Incidental Pulmonary NodulesAmerican Journal of Respiratory and Critical Care Medicine, 2015
- Attitudes and Perceptions About Smoking Cessation in the Context of Lung Cancer ScreeningJAMA Internal Medicine, 2015
- Nicotine Metabolite Ratio (3-Hydroxycotinine/Cotinine) in Plasma and Urine by Different Analytical Methods and Laboratories: Implications for Clinical ImplementationCancer Epidemiology, Biomarkers & Prevention, 2015
- Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trialThe Lancet Respiratory Medicine, 2015
- Results of Initial Low-Dose Computed Tomographic Screening for Lung CancerNew England Journal of Medicine, 2013